SK 1403

Drug Profile

SK 1403

Alternative Names: AJT-240; SK1403

Latest Information Update: 22 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ajinomoto Pharma
  • Developer Sanwa Kagaku Kenkyusho
  • Class
  • Mechanism of Action Calcium-sensing receptor agonists; Parathyroid hormone receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Hyperparathyroidism

Most Recent Events

  • 31 Oct 2017 EA Pharma out-licenses AJT 240 to JW Pharmaceuticals in South Korea
  • 20 Jun 2017 Phase-II clinical trials in Hyperparathyroidism in Japan (unspecified route) (NCT03226171)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top